8-K: Applied Therapeutics' Galactosemia Drug Review Extended by FDA, New Target Date Set

The FDA has extended the review period for Applied Therapeutics' govorestat (AT-007) for Classic Galactosemia by three months, setting a new target date of November 28, 2024.

Summary

• The U.S. Food and Drug Administration (FDA) has extended the review period for Applied Therapeutics' New Drug Application (NDA) for govorestat (AT-007), a treatment for Classic Galactosemia, by three months.
• The new Prescription Drug User Fee Act (PDUFA) target action date is now November 28, 2024.
• The FDA required additional time to review supplemental analyses of previously submitted data, which they deemed a Major Amendment to the NDA.
• In February 2024, the FDA had accepted and granted Priority Review to the NDA.
• Govorestat has been granted Pediatric Rare Disease designation and will qualify for a Priority Review Voucher (PRV) upon approval.
• The NDA filing is supported by data from the Phase 3 ACTION-Galactosemia Kids study, the Phase 1/2 ACTION-Galactosemia study, and preclinical data.
• If approved, govorestat would be the first medication indicated for the treatment of Galactosemia and would be the company's first commercial product.
• A Marketing Authorization Application (MAA) for govorestat has also been submitted to the European Medicines Agency (EMA), with a decision expected in the fourth quarter of 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the delay in the FDA review, which introduces uncertainty and potential delays in commercialization. However, the underlying potential of the drug and the priority review status provide some positive aspects.

Positives

• Govorestat has been granted Pediatric Rare Disease designation, which could lead to faster approval.
• The drug is supported by positive clinical data from multiple trials.
• If approved, govorestat would be the first medication for Galactosemia, giving the company a first-mover advantage.
• The company has also submitted a Marketing Authorization Application to the EMA, expanding the potential market.

Negatives

• The FDA has extended the review period by three months, which could delay the launch of the drug.
• The FDA considered the additional data submitted by the company as a Major Amendment to the NDA, which suggests the initial submission may have been incomplete.

Risks

• There is no guarantee that the FDA or EMA will approve govorestat.
• The company may face challenges in commercializing the drug if approved.
• The company's future revenue and capital requirements are uncertain.
• The company faces competition in the market.
• The company's intellectual property position could be challenged.

Future Outlook

The company anticipates a decision from the EMA on their Marketing Authorization Application in the fourth quarter of 2024, and is awaiting the FDA's decision on the NDA with a new target date of November 28, 2024. The company acknowledges the risks and uncertainties associated with these regulatory processes.

Management Comments

• The company announced that the FDA has extended the review period for the NDA for govorestat.
• The company stated that the FDA required additional time to review supplemental analyses of previously submitted data.

Industry Context

This announcement is significant in the rare disease pharmaceutical space, as govorestat, if approved, would be the first medication for Galactosemia. The delay in the FDA review is not uncommon in the drug approval process, particularly for novel therapies.

Comparison to Industry Standards

• The FDA's extension of the review period is not unusual for complex drug applications, especially those involving novel therapies and rare diseases.
• The three-month extension is within the typical range for major amendments to NDAs.
• Other companies developing treatments for rare diseases, such as BioMarin Pharmaceutical and Ultragenyx Pharmaceutical, have also experienced similar delays in regulatory reviews.
• The granting of Priority Review and Pediatric Rare Disease designation are positive indicators, aligning with industry standards for expedited review of drugs for unmet medical needs.

Stakeholder Impact

• Shareholders may react negatively to the delay in the FDA review.
• Patients with Galactosemia and their families may experience disappointment due to the delay in potential treatment availability.
• Employees of Applied Therapeutics may face increased pressure to meet the new regulatory deadlines.

Next Steps

• The company will continue to work with the FDA to address their questions and concerns.
• The company will await the FDA's decision on the NDA by the new target date of November 28, 2024.
• The company will await the EMA's decision on the MAA in the fourth quarter of 2024.

Key Dates

Keywords

Galactosemia, Govorestat, AT-007, FDA, PDUFA, NDA, EMA, MAA, Priority Review, Rare Disease, Pharmaceuticals, Drug Development